Every material Form 8-K Medpace filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Medpace reported third quarter 2026 revenue of $716.0 million, up 8.5%, and GAAP diluted earnings of $4.84 per share, up from $3.86 a year earlier. The company also replaced its prior buyback, which had $527.0 million remaining, with a new authorization of up to $1.0 billion of common stock through December 31, 2028, funded from cash on hand.
Q3 2026 revenue $716.0 million, up 8.5% from $659.9 million; net new business awards $873.4 million, up 10.6%
Q3 2026 GAAP net income $137.5 million ($4.84 per diluted share) vs. $111.1 million ($3.86) a year earlier; EBITDA $172.1 million, up 16.0%
New repurchase authorization of up to $1.0 billion through December 31, 2028, effective October 20, 2026, replacing the prior authorization with $527.0 million remaining
The filing gives 2026 full-year guidance of $2.835 billion to $2.855 billion in revenue and $17.97 to $18.32 in diluted EPS, with no prior guidance included for comparison
Medpace reported second quarter 2026 revenue of $707.3 million, up 17.2% from a year earlier, and GAAP net income of $121.4 million, or $4.25 per diluted share, compared with $3.10 a year earlier. The company also forecast full-year 2026 revenue of $2.805 billion to $2.885 billion and diluted EPS of $17.25 to $17.95.
Q2 2026 revenue $707.3 million, up 17.2% from $603.3 million in Q2 2025
Q2 2026 GAAP net income $121.4 million ($4.25 diluted EPS) vs. $90.3 million ($3.10) a year earlier
Q2 2026 net new business awards $795.7 million, up 28.2%; book-to-bill ratio 1.13x
Full-year 2026 guidance: revenue $2.805 billion to $2.885 billion; GAAP net income $494.0 million to $514.0 million
Medpace Holdings appointed Brad W. Hansman, age 43, as Executive Vice President, Operations, effective June 1, 2026. He will perform the functions of the company's principal operating officer alongside Susan E. Burwig, the current Executive Vice President, Operations. The filing discloses a $492,250 base salary and incentive eligibility, which is a routine leadership change for shareholders.
Brad W. Hansman, age 43, appointed Executive Vice President, Operations, effective June 1, 2026
Hansman will share principal operating officer duties with Susan E. Burwig
Annual base salary of $492,250, plus eligibility for short-term incentive and long-term equity plans
Medpace reported first quarter 2026 revenue of $706.6 million, up 26.5% from a year earlier, and GAAP diluted earnings of $4.28 per share, up from $3.67. Net income margin fell to 17.5% from 20.5%, and the company set full-year 2026 revenue guidance of $2.755 billion to $2.855 billion. President Jesse Geiger also notified the company he will retire effective May 31, 2026, and CEO August Troendle will assume the president role until a successor is appointed.
Q1 2026 revenue $706.6 million, up 26.5% from $558.6 million; GAAP net income $123.9 million, or $4.28 per diluted share, versus $114.6 million, or $3.67, a year earlier
Q1 2026 EBITDA $149.4 million, up 25.9%; net income margin 17.5% versus 20.5% in Q1 2025
2026 guidance: revenue $2.755 billion to $2.855 billion; GAAP diluted EPS $16.68 to $17.50
Jesse Geiger to retire as President effective May 31, 2026; not due to any disagreement with the company
Medpace reported fourth-quarter and full-year 2025 results on February 9, 2026. Revenue and GAAP earnings per diluted share both rose from the prior-year periods, and the company gave a 2026 forecast for revenue, GAAP net income and EBITDA, with the forecast implying slower revenue growth than in 2025.
Q4 2025 revenue was $708.5 million, up 32.0% from $536.6 million; GAAP diluted EPS was $4.67 versus $3.67.
Full-year 2025 revenue was $2.53 billion, up 20.0%; GAAP diluted EPS was $15.28 versus $12.63.
2026 guidance: revenue of $2.755 billion to $2.855 billion (8.9% to 12.8% growth) and GAAP diluted EPS of $16.68 to $17.50.
No share repurchases in Q4 2025; $821.7 million remained under the buyback program at December 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Medpace filing is on SEC EDGAR ↗. 8-K briefs of other companies →